Amphastar Pharmaceuticals, Inc. AMPH Income Statement

Amphastar pharmaceuticals, inc. (AMPH)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Sep'13	Jun'13
Net revenues
84,688	83,383	80,137	79,047	79,790	89,690	75,543	71,040	58,393	60,402	57,916	65,187	56,670	63,543	64,223	68,033	59,366	76,912	63,868	53,853	56,886	55,877	59,711	49,003	45,870	59,318	62,524
Cost of revenues
47,865	50,002	44,885	46,660	48,887	55,001	46,283	44,976	41,421	40,021	37,363	38,440	33,842	43,575	36,611	36,319	34,464	43,741	46,290	40,535	43,606	43,916	47,920	34,007	33,362	39,038	35,035
Gross profit
36,823	33,381	35,252	32,387	30,903	34,689	29,260	26,064	16,972	20,381	20,553	26,747	22,828	19,968	27,612	31,714	24,902	33,171	17,578	13,318	13,280	11,961	11,791	14,996	12,508	20,280	27,489
Operating (income) expenses:
Selling, distribution, and marketing
3,294	3,476	3,221	2,992	3,141	2,596	1,963	1,876	1,721	1,629	1,756	1,596	1,479	1,491	1,291	1,332	1,352	1,307	1,171	1,470	1,522	1,499	1,454	1,352	1,259	1,462	1,203
General and administrative
10,746	10,505	11,021	12,426	16,327	13,814	13,407	11,669	10,998	9,221	11,665	12,234	11,338	10,703	10,801	9,458	10,870	8,711	9,034	11,308	12,451	9,770	9,556	8,638	6,845	9,545	6,513
Research and development
15,303	19,644	18,606	15,996	14,607	16,734	11,340	15,460	14,030	11,446	10,075	10,732	11,250	12,600	9,723	10,594	8,605	8,860	11,117	10,726	6,568	8,078	8,585	5,994	6,209	9,041	7,791
Gain on sale of intangible assets
-	-	-	-	-	-	-	-	-	0	0	0	2,643	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of long-lived assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	74	-	-	13	184	164	6	0
Total operating expenses
29,343	33,625	32,848	31,414	34,075	33,144	26,710	29,005	26,749	22,296	23,496	24,562	21,424	24,794	21,815	21,384	20,827	18,800	21,326	23,578	20,541	18,986	19,608	16,168	14,477	20,054	15,507
Income (loss) from operations
7,480	-244	2,404	973	-3,172	1,545	2,550	-2,941	-9,777	-1,915	-2,943	2,185	1,404	-4,826	5,797	10,330	4,075	14,371	-3,748	-10,260	-7,261	-7,025	-7,817	-1,172	-1,969	226	11,982
Non-operating (expenses) income:
Interest income
153	256	450	143	148	121	105	106	124	123	124	87	91	83	63	50	74	75	83	65	92	89	94	32	28	49	47
Interest expense
76	43	22	24	30	1	124	100	18	134	264	237	191	54	281	305	384	204	232	210	341	-551	504	476	180	195	237
Other income (expenses), net
-1,752	1,217	-1,250	60,001	-579	-1,076	43	-1,265	782	612	969	1,138	200	-142	422	-323	51	-3,904	-379	176	1,313	568	243	-260	-350	255	127
Total non-operating (expenses) income, net
-1,675	1,430	-822	60,120	-461	-956	24	-1,259	888	601	829	988	100	-113	204	-578	-259	-4,033	-528	31	1,064	1,208	-167	-704	-502	109	-63
Income (loss) before income taxes
5,805	1,186	1,582	61,093	-3,633	589	2,574	-4,200	-8,889	-1,314	-2,114	3,173	1,504	-4,939	6,001	9,752	3,816	10,338	-4,276	-10,229	-6,197	-5,817	-7,984	-1,876	-2,471	335	11,919
Income tax provision (benefit)
2,280	431	598	14,173	-1,479	-1,129	958	-1,347	-1,748	-1,997	-2,213	1,201	611	-1,485	2,111	2,857	1,327	2,805	-1,268	-3,582	-5,532	-3,296	-2,605	-696	-852	494	4,109
Net income (loss)
3,525	755	984	46,920	-2,154	1,718	1,616	-2,853	-7,141	-	99	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss attributable to non-controlling interests
-424	1,781	-326	-867	-3,022	-	-773	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.
3,949	-1,026	1,310	47,787	868	1,867	2,389	-2,853	-7,141	683	99	1,972	893	-3,454	3,890	6,895	2,489	7,533	-3,008	-6,647	-665	-2,521	-5,379	-1,180	-1,619	-159	7,810
Net income (loss) per share attributable to Amphastar Pharmaceuticals, Inc. shareholders:
Basic (in Dollars per share)
0.09	-0.02	0.03	1.01	0.02	0.04	0.05	-0.06	-0.15	0.02	0.00	0.04	0.02	-0.08	0.09	0.15	0.06	0.17	-0.07	-0.15	-0.01	-0.06	-0.12	-0.03	-0.04	0.00	0.20
Diluted (in Dollars per share)
0.08	-0.03	0.03	0.96	0.02	0.04	0.05	-0.06	-0.15	0.02	0.00	0.04	0.02	-0.07	0.08	0.15	0.05	0.17	-0.07	-0.15	-0.01	-0.06	-0.12	-0.03	-0.04	0.00	0.20
Weighted-average shares used to compute net income (loss) per share attributable to Amphastar Pharmaceuticals, Inc. shareholders:
Basic (in Shares)
46,408	46,838	47,239	47,107	46,744	46,268	46,241	46,557	46,514	46,233	46,101	46,025	46,069	46,104	45,398	44,957	45,041	45,084	45,310	44,849	44,601	44,648	44,644	39,767	38,769	38,709	38,708
Diluted (in Shares)
48,248	49,243	50,075	49,894	50,416	44,228	48,281	46,557	46,514	49,330	48,215	47,866	48,057	49,285	47,953	45,968	46,810	45,084	45,310	44,849	44,601	44,648	44,644	39,767	38,769	38,709	38,847